INTRODUCTION
Adrenal insufficiency is caused by failure of the adrenal cortex to produce cortisol. This can result from loss of function of the adrenal glands, i.e. primary adrenal insufficiency, most frequently caused by autoimmune adrenalitis ("Addison's disease") and inborn disruption of glucocorticoid synthesis by congenital adrenal hyperplasia [1] [2] [3] [4] . Secondary adrenal insufficiency is caused by impaired hypothalamic-pituitary regulation of adrenal cortisol synthesis, mostly caused by tumours of the hypothalamic-pituitary region and their treatment by surgery or radiotherapy 5 .
However, chronic exogenous glucocorticoid treatment also invariably causes adrenal insufficiency, with potential reversibility following gradual withdrawal.
The clinical phenotype of primary adrenal insufficiency was first described by Thomas Addison in 1855 6 , a fatal disease until corticosteroid replacement became available. Two years after
Edward Kendall first isolated corticosterone in 1936, Simpson used synthetic deoxycorticosterone acetate in the treatment of Addison's disease with success 7 . However, widespread availability of glucocorticoids was only achieved by the synthesis of cortisone, transforming the life of patients with rheumatoid arthritis 8 and prompting the award of the Nobel Prize in Medicine to Kendall, Philip Hench and Tadeusz Reichstein in 1950.
Today, despite these achievements, adrenal insufficiency continues to present significant challenges regarding diagnosis, optimised replacement therapy and long-term health outcomes including quality of life and mortality. This review represents a comprehensive update of our last major review 9 , focussing on controversies and new developments. to capture developments since publication of our last comprehensive review 9 .
CAUSES OF ADRENAL INSUFFICIENCY Causes of primary adrenal insufficiency
In developed countries, autoimmune-mediated adrenalitis with subsequent destruction of adrenal tissue is the most common cause of primary adrenal insufficiency, accounting for 68-94% of cases 10 ; it can occur in isolation (30-40%) or in combination with other autoimmune diseases as part of autoimmune polyglandular syndromes (APS) type 1 (10-15%) and type 2 (50-60%) ( Table   1 ). APS1 (or APECED, autoimmune polyendocrinopathy with adrenal insufficiency and hypoparathyroidism, mucocutaneous candidiasis, ectodermal dystrophy) is a monogenic disease, caused by mutations in the autoimmune regulator gene AIRE, while several disease susceptibility genes have been identified for APS2 and isolated Addison's disease (CTLA4, PTPN22, MICA
5.1)
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. The latter are also associated with distinct alleles and haplotypes within the major histocompatibility complex human leukocyte antigen (HLA) including DR3-DQ2, DR4-DQ8 and DRB1 0301 and 0404 11 . 12 .
The most frequent monogenic cause of adrenal insufficiency is congenital adrenal hyperplasia, which is identical in prevalence to autoimmune adrenalitis ( 
Drug-induced adrenal insufficiency
Numerous drugs can result in decreased cortisol synthesis, increased cortisol inactivation or impaired glucocorticoid action ( Table 1) . The most common cause of drug-induced adrenal insufficiency is the suppression of the hypothalamic-pituitary-adrenal axis by exogenous glucocorticoid doses ≥5mg prednisolone equivalent for more than four weeks, irrespective of mode of delivery (topical, inhaled, oral or injected). Similarly, patients with Cushing's syndrome are rendered adrenal insufficient by successful treatment of the endogenous cortisol excess.
Recovery of the hypothalamic-pituitary adrenal axis can take many months and time to recovery corresponds to some degree with the preceding period of glucocorticoid excess 14, 15 . Cortisol response to ACTH is slightly higher at 60 than at 30 min Cortisol secretion follows a characteristic diurnal rhythm, rising in the early morning hours (2-4am), peaking in the morning (6-9 a.m.) and then descending to low levels in the evening and very low levels around midnight 23 . Random morning cortisol levels <80nmol/L (3µg/dl) are strongly predictive of adrenal insufficiency 24 . However, to safely establish the diagnosis of adrenal insufficiency, an ACTH stimulation test should always be performed. Importantly, diagnostic tests should never delay the prompt initiation of life-saving hydrocortisone treatment in suspected adrenal crisis; formal confirmation of diagnosis can be safely carried out after clinical recovery.
Measurement of plasma ACTH is the mandatory first step in the differential diagnosis of adrenal insufficiency ( Figure 1 ). In primary adrenal insufficiency, ACTH levels are usually >100pg/mL (22pmol/L) 25 ; plasma renin will also be elevated, with concomitantly low serum aldosterone. In secondary adrenal insufficiency, ACTH levels will be low or inappropriately normal while mineralocorticoid secretion is sufficient. Serum DHEAS will be invariably low in both primary and secondary adrenal insufficiency.
In secondary adrenal insufficiency, where adrenal atrophy ensues from lack of endogenous ACTH stimulation, the short synacthen test is also generally useful. However, within four weeks of a pituitary insult/surgery the adrenal glands are not yet atrophied and thus will still be responsive to ACTH, which could wrongly indicate an intact HPA axis. Early postoperative morning cortisol levels >275nmol/L (10µg/dl) were shown to be an accurate predictor of a normal corticotroph reserve 26, 27 . The long-term predictive value of short synacthen test cut-offs of 510 and 550nmol/L were evaluated retrospectively in a large cohort of patients investigated for secondary adrenal insufficiency and demonstrated a very low incidence of false negative results (2/178 patients) 28 .
The insulin tolerance test is the gold standard for diagnosis of secondary adrenal insufficiency but the testing procedure is cumbersome, expensive to carry out and can be unsafe in patients with history of seizures and cardiac disease; special care should be taken if the test is carried out in children or elderly patients. Achieving or failing to achieve an adequate hypoglycaemia (2.2 mmol/L (<40 mg/dl)) are additional limiting factors. Usually 0.1U insulin per kg body weight is used, however around a third of patients need more 29 . Peak cortisol levels <500nmol/L (18µg/dl) are considered diagnostic for adrenal insufficiency 30 .
DIFFERENTIAL DIAGNOSIS AND CONFIRMATION OF ETIOLOGY
In primary adrenal insufficiency, increased antibody titres against 21-hydroxylase and adrenal cortex are indicators of autoimmune adrenalitis 31 , the most frequent cause of disease once congenital adrenal hyperplasia is ruled out. Therefore measurement of relevant auto-antibodies is the logical first step in differential diagnosis. If neither the family history nor antibody titre point toward autoimmune pathogenesis, then further investigations should be undertaken ( Figure 1 ).
However, autoimmune adrenalitis is still the most likely underlying cause as many patients turn antibody negative when autoimmune destruction has progressed for some time.
Screening for congenital adrenal hyperplasia in adults with adrenal insufficiency consists of serum 17-hydroxyprogesterone at baseline and after ACTH. In antibody-negative patients, adrenal imaging is helpful and can reveal infiltrative processes, infection or haemorrhage.
Bilateral metastases of solid organ tumours such as lung, breast and kidney are associated with an increased risk of adrenal insufficiency 32 ; therefore such patients should undergo screening by a short synacthen test. In antibody-negative men, screening for plasma very long chain fatty acids should be carried out, to exclude adrenoleukodystrophy, even if no neurological signs are present.
In and in haemodynamically stable patients also a short synacthen test can be performed; however, if in doubt, it is better to treat promptly and confirm the diagnosis later after the patient is better.
Increased or reduced corticosteroid-binding globulin concentrations: More than 90% of circulating cortisol is bound to corticosteroid binding globulin (CBG) and only the remaining free fraction is biologically active 33 . Although not routinely advocated, there are special circumstances in which measurement of serum free cortisol and/or CBG may be useful. CBG is decreased during acute illness, in severe liver disease and in the rare patients with CBG gene mutations.
Enhanced oestrogen action, e.g. during pregnancy or intake of oral contraceptives, significantly increases CBG, resulting in increased total cortisol but unchanged free cortisol. The latter is not routinely measured and studies on normal reference values in pregnancy are currently lacking.
Data on the utility of salivary cortisol are too limited for firm recommendations 34, 35 .
Patients on exogenous steroids: Current or recent exogenous glucocorticoid therapy can complicate interpretation of ACTH test results. Careful review of treatment history during the last 12 months (including administration of topical, inhaled, intranasal, epidural or intra-articular preparations) is essential. A further important consideration is the possibility that some synthetic glucocorticoids can cross-react with the immunoassays used to measure circulating cortisol in many routine biochemistry laboratories 36 .
Assessing the adequacy of adrenal reserve in patients who are undergoing planned withdrawal of chronic exogenous glucocorticoid treatment can be challenging 37 . Supraphysiological glucocorticoid therapy causes adrenal atrophy that is slowly reversible in the majority of cases.
However, there is considerable inter-individual variability in the degree of hypothalamicpituitary-adrenal axis suppression and the time to recovery 14 . Glucocorticoids should be slowly tapered and if there is no ongoing indication for glucocorticoid therapy other than adrenal insufficiency, long-acting glucocorticoids should ideally be switched to hydrocortisone.
Assessment of adrenal function can be undertaken after hydrocortisone has been temporarily stopped for 24 hours prior to ACTH 1-24 stimulation testing. Prednisone, prednisolone and dexamethasone may impact on results for at least 48-72 hours if not longer, hence switching to hydrocortisone prior to comprehensive testing of adrenal reserve is often more prudent.
All modes of glucocorticoid administration (oral, inhaled, intranasal, topical, intra-articular, intramuscular and intra-venous) have been associated with hypothalamic-pituitary-adrenal axis suppression, which may be present in half of the patients taking inhaled glucocorticoid therapy [38] [39] [40] , though the true magnitude of this problem and the clinical consequences are still largely unknown and data on optimised diagnostic work-up are limited. If there are signs and symptoms suggestive of adrenal insufficiency, dynamic assessment of adrenal reserve should be undertaken, but routine screening in all patients on inhaled, topical or intranasal therapy is not recommended.
Often, it is not possible to omit glucocorticoid therapy, even for a short period of time (inhaled glucocorticoids for asthma), further complicating the assessment. It is important to take a multidisciplinary team approach to clarify whether supraphysiological glucocorticoid therapy is still required or whether glucocorticoids can be carefully tapered. Management can be complex and a balance between the prevention of adrenal crisis and minimizing glucocorticoid excess.
CHRONIC REPLACEMENT THERAPY Glucocorticoid replacement
Daily physiological production of cortisol is around 5-6 mg/m 2 body surface area 41 . Currently recommended hydrocortisone doses are 15-25 mg, usually administered in two to three daily doses, with 50-66% of the daily dose administered in the morning upon awakening 9 . The second dose is usually administered 6-8 hours after the morning dose; if a thrice daily regimen is followed the second dose is administered 4-6 hours after the early morning dose and the third dose 4-6 hours thereafter. Some recommend weight-adjusted dosing to achieve reduction in intervals of excess in cortisol levels during the day and decreased variability of cortisol profiles 42 .
Decision on number of doses is also based on patient preference, differences in daily activity and experience.
As there is no reliable biochemical marker to assess the appropriateness of glucocorticoid replacement dose, dose modification is guided by clinical judgment, subjective perception of symptoms and signs and symptoms of glucocorticoid under-and over-replacement, respectively.
The goal is to achieve the best clinical result with the lowest possible daily dose of steroid.
Cortisol day curves are of limited value in routine monitoring 43 . In our experience, timed measurement of serum cortisol is only of value if malabsorption or increased metabolic clearance is suspected. Monitoring plasma ACTH is not useful. Urinary 24-h free cortisol excretion shows considerable inter-individual variability and comparison to normal reference ranges are not useful as due to the pharmacokinetic properties of current glucocorticoid preparations the kidney excretion threshold is much more quickly overcome after exogenous administration of glucocorticoids.
A global survey of more than 1000 patients with mostly primary adrenal insufficiency revealed that hydrocortisone is most commonly used (75%), followed by prednisone/prednisolone (11%), cortisone acetate (6%) and dexamethasone (4%) 44 . Cortisone acetate (1.6 hydrocortisone equivalent) and prednisone (0.25 hydrocortisone equivalent) require intrahepatic activation to cortisol and prednisolone (0.20mg hydrocortisone equivalent), respectively, by 11β-hydroxysteroid dehydrogenase type 1, which might lead to a higher pharmacokinetic variability compared to hydrocortisone. The long-lasting synthetic steroids prednisone and dexamethasone (0.025 hydrocortisone equivalent) exert strong anti-inflammatory action and hence are frequently used in chronic inflammatory conditions.
Over the last few years progress has been made in the development of steroid preparations aiming to provide a more circadian-based serum cortisol profile 23 . This was pioneered by the demonstration of superior biochemical control as well as indications of improved quality of life in adrenal insufficiency patients receiving intravenous and subcutaneous hydrocortisone infusions 45 .
An approved option for modified release oral hydrocortisone is Duocort that provides longer acting delivery of hydrocortisone, however, fails to resurrect physiologic early morning secretion of cortisol. An early rise in morning cortisol can be achieved by modified and delayed release glucocorticoid preparations, such as prednisone delayed-release tablets and, possibly more physiologically, by the modified and delayed release hydrocortisone preparation Chronocort that is currently under development 23, 46 . However, data from larger clinical trials on the beneficial impact of these newer preparations in patients with adrenal insufficiency are currently still Adrenal androgen precursor replacement:
In women, androgen production by the adrenal glands is the main source of androgens; therefore, adrenal insufficiency is invariably associated with severe androgen deficiency in women. Serum DHEAS concentrations physiologically peak between 20-30 years, followed by a gradual decline 47 that is independent of menopause. The adrenal androgen precursor dehydroepiandrosterone, DHEA, is activated to sex steroids in a wide variety of peripheral tissues and in the gonads, but has also neurosteroidal activity in the brain. DHEA supplementation in adrenal insufficiency has been shown to improve overall wellbeing [48] [49] [50] [51] , depression and anxiety scores 48, 52 and sexual interest and satisfaction 48 End-stage renal disease: In patients requiring dialysis, fludrocortisone is no longer needed and can be stopped; it is important to plan daily glucocorticoid replacement considering the fact that significant amounts of the morning glucocorticoid dose may be lost through haemodialysis.
Treatment and prevention of acute adrenal crisis
Adrenal crisis represents a life-threatening emergency. Therefore, prevention is of key importance. The frequency of crisis has been reported as 6-8/100 patient years, with around a half of patients with Addison's disease reporting at least one previous adrenal crisis 58, 59 . Most frequent precipitating causes are gastroenteritis and fever (60-70%), but also other stressful events such as trauma, surgery, dental procedure and also major psychological distress 58, 59 . Many crises result from failure to adjust glucocorticoid dose appropriately or at all; this is also caused to a significant degree by limited knowledge and slow reaction time of physicians involved in the acute care of adrenal insufficiency patients with incipient crisis 59, 60 . Patients with other comorbidities such as diabetes mellitus, diabetes insipidus, asthma and premature ovarian failure are at higher risk, but this does not sufficiently discriminate those patients with increased risk of adrenal crisis 58, 59 . Symptoms include fatigue, nausea, vomiting, abdominal pain, muscle cramps, hypotension and can accelerate to hypovolaemic shock and coma. Hyponatraemia, hyperkalaemia and prerenal failure are frequently noted; hypoglycaemia is rarely observed in adults, but relatively frequent in children in whom it can significantly affect neurological outcome.
Treatment includes prompt rehydration (1000ml of physiological saline in the first hour, 500 ml in the second hour followed by continuous fluid administration) and immediate parenteral administration of 100 mg hydrocortisone, followed by 200mg/24h, ideally per continuous i.v. Mineralocorticoid administration should be initiated as soon as total daily hydrocortisone dose is less than 50mg 25 .
Adequate prevention and treatment of adrenal crisis are of highest importance to avoid fatal outcomes. As adrenal insufficiency is a rare disease, many physicians are not familiar with its management often resulting in critical delays in emergency treatment. Education of patients and relatives must provide information on correct adjustment of glucocorticoid replacement (sick day rules), symptom awareness, and steroid emergency card and medical alert bracelets ( Table 2) .
The development and Europe-wide roll out of a steroid emergency card aiming to encourage the treating physician to immediately administer hydrocortisone in case of imminent crisis is currently under way.
Emergency self-administration of hydrocortisone is of key importance to prevent crisis-related morbidity and mortality. In a 2006 survey 66% of Addison patients reporting a crisis had relied on medical personnel to administer the first treatment; only 12% of patients self-administered a hydrocortisone injection, with another 17% treated by a close person. Almost a third of patients did not have an emergency injection kit 58 .
As an alternative to intramuscular injection, which some patients are hesitant to administer promptly, subcutaneous injections might be an alternative, generating similar pharmacokinetics to intramuscular injection 61 . Suppositories containing 100 mg of prednisolone can be used based on patient's preference 62 . Progress in this area will be achieved once pharmaceutical companies make progress in the development of a suitable self-injection device similar to the epinephrine auto-injector for patients with anaphylaxis.
FERTILITY AND PREGNANCY
Women with Addison's disease have reduced rates of fertility, even after exclusion of women with premature ovarian failure 63, 64 . An increased risk of miscarriage has also been reported.
Women with Addison's disease also suffer higher rates of preterm birth and Caesarean delivery and more likely to have newborns with low birth weight (<2500g) 64 . While women with adrenal insufficiency due congenital adrenal hyperplasia may often require Caesarean delivery, if there was previous genital correction surgery, other women with adrenal insufficiency should not require Caesarean delivery any more frequently than women in the normal population.
Physiologically, total cortisol concentrations are 2-3 times increased in pregnancy 65 , rising in the first trimester due to higher CBG levels and increased cortisol half-life secondary to decreases in hepatic clearance of the bound hormone 66 . However, from the 22 nd week of gestation onwards also free cortisol levels increase significantly, most likely due to increased placental production of CRH. This results in hypertrophy of adrenal glands and increased responsiveness to synacthen as the pregnancy progresses 35, 67 , with diagnostic and therapeutic implications.
Adrenal insufficiency symptoms overlap with symptoms that might be related to pregnancy itself, such as fatigue, hyponatraemia, nausea and vomiting. The short synacthen stimulation test remains the test of choice in pregnant women if adrenal insufficiency is suspected. In a small cohort of healthy pregnant women the peak total cortisol response after ACTH injection was significantly higher in comparison to the non-pregnant state (median of 1000 nmol/L (37 µg/dl) in the second and third trimester versus 700 nmol/L (26 µg/dl) postpartum) 35 . Thus, it is prudent to use higher total cortisol cut-offs for confirming a diagnosis of adrenal insufficiency until more data is available; diagnostic cut-offs of 700nmol/L (25µg/dl), 800nmol/L (29µg/dl) and 900nmol/L (32µg/dl) for the first, second and third trimester, respectively, have been recommended 68 . Although adrenal crisis due to failing to adapt the dose of glucocorticoid during pregnancy has been reported 59 , little evidence exists on the optimal glucocorticoid replacement during pregnancy 84. Our usual practice is to increase hydrocortisone dose by around 20-40% during the third trimester to reflect the physiologic increase in free cortisol.
Clinical assessment of mineralocorticoid requirements during pregnancy is difficult, again due to overlapping unspecific symptoms, such as oedema or postural hypotension. Sodium and potassium can be monitored in blood and urine; however plasma renin is not informative as levels physiologically increase during pregnancy. Increasing progesterone levels during pregnancy exert an anti-mineralocorticoid effect, thus it is sometimes required to adjust fludrocortisone dose 69 .
During delivery hydrocortisone replacement should be similar to that in major surgical stress; . The reduction in QoL despite established replacement therapy might be related to glucocorticoid over-or under-replacement, non-physiological circadian cortisol pattern generated by the currently available hydrocortisone preparations 71, 72 or to lack of adrenal androgen replacement 48, 51 , indicating in principle an urgent need for improved replacement strategies 73 . In retrospective analyses, QoL was negatively correlated with the glucocorticoid dose and was still reduced in patients receiving DHEA replacement 70 . This suggests that non-physiological glucocorticoid replacement may play a major role. A small study restoring the circadian profile by administration of hydrocortisone via insulin pump demonstrated an increase of QoL 74 .
Convincing data on optimal interventions in order to improve QoL however, is still lacking despite growing interest.
PROGNOSIS
In general, the prognosis for appropriately diagnosed and treated patients with adrenal insufficiency is good. However, it remains a potentially lethal condition and adrenal crisis remains one of the frequent causes of death, in particular in younger patients 75 . Standardized mortality rates are more than double that of the age and sex adjusted control population in both primary and secondary adrenal insufficiency patients 5, [76] [77] [78] . Increased mortality in primary adrenal insufficiency is linked to increased rate of mainly respiratory infections 77 and, in particular in patients <40 years, also to adrenal crisis and sudden death 75 .
In clinical practice, a significant proportion of patients regularly take replacement doses that are in excess of normal physiological levels, often to try to alleviate many of their symptoms. In addition, previous over-estimates of physiological cortisol production rates may have led to prescribed doses in excess of physiological requirements Addison's disease taking 30mg hydrocortisone 82 . Interestingly, a more adverse metabolic response was noted when hydrocortisone was administered in the evening 83 . Studies have also
shown an increased incidence of osteoporosis in patients receiving >30 mg of HC or 7.5 mg prednisone per day 43, 84 and an increased risk of fractures in Addison patients 85 . However, currently recommended replacement doses of 15-25 mg per day do not affect bone density 86 .
In conclusion, despite significant advances over the last decade, the diagnosis and management of adrenal insufficiency still presents challenges and requires consideration of special situations to tailor replacement therapy to the individual patient. Raising awareness and education of both medical teams and patients on adrenal insufficiency and management of adrenal crisis is of paramount importance to improve clinical outcome. It remains to be demonstrated whether modified release hydrocortisone preparations will provide a novel avenue for more physiologic replacement able to improve quality of life and prevent metabolic consequences.
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